Mohammad A Hossain

US Patent:

20110206699, Aug 25, 2011

Filed:

Oct 2, 2009

Appl. No.:

13/121016

Inventors:

Mohammad S. Hossain - Norcross GA, US
Andrew T. Gewitz - Smyrna GA, US
John D. Roback - Smyrna GA, US
Edmund K. Waller - Atlanta GA, US

Assignee:

EMORY UNIVERSITY - Atlanta GA

International Classification:

A61K 39/395
A61K 39/02
A61K 39/112
A61P 37/06

US Classification:

4241721, 4242341, 4242581

Abstract:

Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject.

US Patent:

20170258904, Sep 14, 2017

Filed:

May 22, 2017

Appl. No.:

15/601352

Inventors:

- Atlanta GA, US
Jian-Ming Li - Atlanta GA, US
Mohammad Hossain - Lilburn GA, US

International Classification:

A61K 39/395
A61K 38/22
A61K 35/14
A61K 38/04
A61K 39/245
A61K 38/16
A61K 35/17

Abstract:

Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell.